WO2001083535A3 - Polypeptides for use as a vaccine and/or treatment for hiv infection - Google Patents

Polypeptides for use as a vaccine and/or treatment for hiv infection Download PDF

Info

Publication number
WO2001083535A3
WO2001083535A3 PCT/CA2001/000586 CA0100586W WO0183535A3 WO 2001083535 A3 WO2001083535 A3 WO 2001083535A3 CA 0100586 W CA0100586 W CA 0100586W WO 0183535 A3 WO0183535 A3 WO 0183535A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
vaccine
treatment
hiv infection
purportedly
Prior art date
Application number
PCT/CA2001/000586
Other languages
French (fr)
Other versions
WO2001083535A2 (en
Inventor
Jamie K Scott
Carlos F Barbas Iii
Paul W H I Parren
Dennis R Burton
Michael B Zwick
Original Assignee
Univ Fraser Simon
Scrips Res Inst
Jamie K Scott
Carlos F Barbas Iii
Paul W H I Parren
Dennis R Burton
Michael B Zwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Fraser Simon, Scrips Res Inst, Jamie K Scott, Carlos F Barbas Iii, Paul W H I Parren, Dennis R Burton, Michael B Zwick filed Critical Univ Fraser Simon
Priority to AU2001254567A priority Critical patent/AU2001254567A1/en
Publication of WO2001083535A2 publication Critical patent/WO2001083535A2/en
Publication of WO2001083535A3 publication Critical patent/WO2001083535A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Novel synthetic polypeptides are provided that represent a neutralizing epitope of the HIV envelope glycoprotein gp 120 that is purportedly involved in the binding of this molecule to its cognate cellular receptor CD4. The polypeptides may be used in vaccine formulations as well as in diagnostic immunoassays, immunotherapy and pharmaceutical compositions.
PCT/CA2001/000586 2000-05-02 2001-05-01 Polypeptides for use as a vaccine and/or treatment for hiv infection WO2001083535A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001254567A AU2001254567A1 (en) 2000-05-02 2001-05-01 Polypeptides for use as a vaccine and/or treatment for hiv infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20127700P 2000-05-02 2000-05-02
US60/201,277 2000-05-02

Publications (2)

Publication Number Publication Date
WO2001083535A2 WO2001083535A2 (en) 2001-11-08
WO2001083535A3 true WO2001083535A3 (en) 2002-10-03

Family

ID=22745202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/000586 WO2001083535A2 (en) 2000-05-02 2001-05-01 Polypeptides for use as a vaccine and/or treatment for hiv infection

Country Status (2)

Country Link
AU (1) AU2001254567A1 (en)
WO (1) WO2001083535A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3718720B2 (en) * 2003-05-23 2005-11-24 国立大学法人 北海道大学 New bioactive peptides isolated from insects

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004273A2 (en) * 1989-09-22 1991-04-04 Idec Pharmaceuticals Corp. Novel peptides associated with the cd4 binding region of gp120 and their methods of use
WO1991017764A1 (en) * 1990-05-16 1991-11-28 Dana Farber Cancer Institute Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
WO1998001564A1 (en) * 1996-07-08 1998-01-15 Genentech, Inc. Hiv envelope polypeptides and vaccine
US5750332A (en) * 1994-01-19 1998-05-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptomers with enhanced immunogenicity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004273A2 (en) * 1989-09-22 1991-04-04 Idec Pharmaceuticals Corp. Novel peptides associated with the cd4 binding region of gp120 and their methods of use
WO1991017764A1 (en) * 1990-05-16 1991-11-28 Dana Farber Cancer Institute Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
US5750332A (en) * 1994-01-19 1998-05-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptomers with enhanced immunogenicity
WO1998001564A1 (en) * 1996-07-08 1998-01-15 Genentech, Inc. Hiv envelope polypeptides and vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FREY A ET AL: "Immunization of mice with peptomers covalently coupled to aluminum oxide nanoparticles", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 23-24, 6 August 1999 (1999-08-06), pages 3007 - 3019, XP004173612, ISSN: 0264-410X *

Also Published As

Publication number Publication date
AU2001254567A1 (en) 2001-11-12
WO2001083535A2 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO1991004273A3 (en) Novel peptides associated with the cd4 binding region of gp120 and their methods of use
CA2082948A1 (en) Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
BR0111016A (en) Sustained-release pharmaceutical compositions for parenteral administration of biologically active hydrophilic compounds
EP2280073A3 (en) Vaccine for prevention and treatment of HIV-infection
AR022008A1 (en) A COMPOSITION OF CONTROLLED GALANTAMINE RELEASE, A PROCESS FOR THE PREPARATION OF THE SAME, AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT
BR9914360A (en) N-aralkylaminotetralins as ligands for neuropeptide receptor yy5
AU2001295673A1 (en) Vaccine composition
EP1731166A3 (en) Streptococcus pneumoniae proteins and vaccines
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
WO2002032943A3 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
WO2003087757A3 (en) Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
WO2002096936A3 (en) Daptomycin and related analogs in crystalline form, their preparation and use
NO986088D0 (en) Polypeptides with the ability to form antigen binding structures with specificity
EP1409694A4 (en) Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
HUP9700826A1 (en) Pharmaceutical compositions against peptic ulcer
WO2003004049A3 (en) Use of polyclonal anti-hiv goat serum as a therapeutic agent
WO2001078682A3 (en) Sustained release drug compositions
CA2337667A1 (en) Dextran-leptin conjugates, pharmaceutical compositions and related methods
WO2001083535A3 (en) Polypeptides for use as a vaccine and/or treatment for hiv infection
WO2001068677A3 (en) Derivatives of breast canacer antigen her-2 for therapeutical use
WO2005065709A3 (en) Lyophilized antibody conjugate formulation
MXPA02012015A (en) Ligands of integrin receptors.
YU35303A (en) Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenyl-amino)-3-pyridylsulfonamide and cyclic oligosaccharides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP